At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NAMS NEWAMSTERDAM PHARMA CO NV
Post-Mkt 08-20 17:29:20 EDT
27.78
-0.75
-2.63%
盘后28.00
+0.22+0.79%
16:46 EDT
High28.43Low27.53Vol744.36K
Open28.26D1 Closing28.53Amplitude3.15%
Mkt Cap3.32BTradable Cap2.55BTotal Shares119.54M
T/O20.66MT/O Rate0.81%Tradable Shares91.69M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

NewAmsterdam Pharma Amends 8-K to Disclose COO Douglas Kling Separation, Advisor Agreement Terms
Reuters  ·  08-15
NewAmsterdam Pharma Amends 8-K to Disclose COO Douglas Kling Separation, Advisor Agreement Terms
NewAmsterdam Pharma Appoints Robert Gunning Principal Accounting Officer
Reuters  ·  08-15
NewAmsterdam Pharma Appoints Robert Gunning Principal Accounting Officer
Needham Remains a Buy on NewAmsterdam Pharma Company (NAMS)
TIPRANKS  ·  08-08
Needham Remains a Buy on NewAmsterdam Pharma Company (NAMS)
NewAmsterdam Pharma Grants 28,000 Inducement Share Options at $27.79 to New Hires
Reuters  ·  08-07
NewAmsterdam Pharma Grants 28,000 Inducement Share Options at $27.79 to New Hires
RBC Adjusts NewAmsterdam Pharma PT to $50 From $51, Maintains Outperform Speculative Risk Rating
MT Newswires Live  ·  08-06
RBC Adjusts NewAmsterdam Pharma PT to $50 From $51, Maintains Outperform Speculative Risk Rating
Stifel Nicolaus Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
TIPRANKS  ·  08-06
Stifel Nicolaus Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
NewAmsterdam Pharma Company N.V. Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-05
NewAmsterdam Pharma Company N.V. Reports Results for the Quarter Ended June 30 - Earnings Summary
Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion for Obicetrapib and Obicetrapib/Ezetimibe
Reuters  ·  08-05
Newamsterdam Pharma Company N.V. - Announces Positive CHMP Opinion for Obicetrapib and Obicetrapib/Ezetimibe
NewAmsterdam Pharma Q2 EPS $(0.52) Misses $(0.48) Estimate, Sales $3.701M Beat $1.663M Estimate
Benzinga Earnings  ·  08-05
NewAmsterdam Pharma Q2 EPS $(0.52) Misses $(0.48) Estimate, Sales $3.701M Beat $1.663M Estimate
NewAmsterdam Pharma Q2 Net Loss Widens to USD 64.1 Million; Revenue Falls to USD 3.7 Million
Reuters  ·  08-05
NewAmsterdam Pharma Q2 Net Loss Widens to USD 64.1 Million; Revenue Falls to USD 3.7 Million
Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
Dow Jones  ·  08-05
Press Release: NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results
Why NewAmsterdam Pharma (NAMS) Is Down 6.2% After EMA Backs Ubeslo And Evlarco Approval
Simply Wall St.  ·  08-03
Why NewAmsterdam Pharma (NAMS) Is Down 6.2% After EMA Backs Ubeslo And Evlarco Approval
NewAmsterdam Pharma to Host Investor Day Webcast for Analysts, Investors
Reuters  ·  07-29
NewAmsterdam Pharma to Host Investor Day Webcast for Analysts, Investors
Truist Financial Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
TIPRANKS  ·  07-27
Truist Financial Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)
Newamsterdam Pharma Says EU CHMP Backs Approval of Ubeslo, Evlarco Cholesterol Drugs
Reuters  ·  07-27
Newamsterdam Pharma Says EU CHMP Backs Approval of Ubeslo, Evlarco Cholesterol Drugs
Newamsterdam Says EU CHMP Backs Ubeslo, Evlarco Cholesterol Drugs for Approval
Reuters  ·  07-26
Newamsterdam Says EU CHMP Backs Ubeslo, Evlarco Cholesterol Drugs for Approval
Analysts’ Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Zevra Therapeutics (ZVRA)
TIPRANKS  ·  07-25
Analysts’ Top Healthcare Picks: NewAmsterdam Pharma Company (NAMS), Zevra Therapeutics (ZVRA)
Newamsterdam Pharma Says EMA Panel Backs EU Approval for Ubeslo, Evlarco Cholesterol Drugs
Reuters  ·  07-24
Newamsterdam Pharma Says EMA Panel Backs EU Approval for Ubeslo, Evlarco Cholesterol Drugs
Newamsterdam Pharma COO Douglas Kling Resigns, Effective Aug. 14
Reuters  ·  07-23
Newamsterdam Pharma COO Douglas Kling Resigns, Effective Aug. 14
Newamsterdam Pharma Chief Accounting Officer Louise Kooij Disposes of Ordinary Shares Worth $3.08 Million
Reuters  ·  07-23
Newamsterdam Pharma Chief Accounting Officer Louise Kooij Disposes of Ordinary Shares Worth $3.08 Million

Introduction

Company Name.
NEWAMSTERDAM PHARMA CO NV
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Issue price:
--